論文発表 / Publication

2016年

2016.04.01 

2016.04.01  Maruta Y., Kuwata T., Tanaka K., Alam M., Ramirez-Valdez K-P., Egami Y., Yoshiaki Suwa Y., Morioka H., Matsushita S. Cross-neutralization activity of single-chain variable fragment (scFv) derived from anti-V3 monoclonal antibodies mediated by post-attachment binding. Jpn. J. Infect. Dis.,69(5):395-404, 2016

2016.04.01  Mizuguchi T., Harada S., Miura T., Ohashi N., Narumi T, Mori H.; Irahara Y; Yamada Y.; Nomura W., Matsushita S., Yoshimura K, Tamamura H. Minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 26:397-400, 2016.

2016.04.01  Boonchawalit, S., Harada, S, Shirai, N., Gatanaga, H., Oka, S., Matsushita, S., and Yoshimura, K. Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization. Jpn. J. Infec.t Dis., in press, 2016.

2016.01.06  Kuwata, T., Enomoto, I., Baba, M. and Matsushita S. Incompatible natures of HIV-1 envelope in resistance to the CCR5 antagonist cenicriviroc and neutralizing antibodies.Antimicrobial Agents and Chemotherapy (AAC)  Accepted manuscript posted online 2 November 2015, doi: 10.1128/AAC.02285-15

2015年

2015.10.20  Ramirez, K., Kuwata, T., Maruta, Y., Tanaka, K., Alam, M., Yoshimura, K., Matsushita, S. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 475, 187-203, 2015.doi:10.1016/j.virol.2014.11.011

2015.10.20  Matsushita, S., Yoshimura, K., Ramirez, k., Pisupati, J., Murakami, T., the KD-1002 Study Group. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS, 29(4), 453-462, 2015. doi: 10.1097/QAD.0000000000000570

2015.01.20  Kirby, K.A., Ong Y.T., Hachiya, A., Laughlin, T.G., Chiang, L.A., Pan, Y., Moran, J.L., Marchand, B., Singh, K., Gallazzi, F., Quinn, T.P., Yoshimura, K., Murakami, T., Matsushita, S., Sarafianos, S.G.. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. The FASEB Journal, 29(1), 70-80, 2015.

2014年

2014.10.20  Yoshimura, K., Harada, S., Boonchawalit, S., Kawanami, Y., and Matsushita, S. Impact of maraviroc-resistant and low-CCR5- adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies. Journal of General Virology, 95, 1816-1826, 2014.

2013年

2013.10.20  Otsuki, H., Hishiki, T., Miura, T., Hashimoto, C., Narumi, T., Tamamura, H., Yoshimura, K., Matsushita, S., and Igarashi, T. Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic. J. Gen. Virol. 94: 2710-2716, 2013.

2013.10.09  Hashimoto, C., Narumi, T., Otsuki, H., Hirota, Y., Arai, H., Yoshimura, K., Harada, S., Ohashi, N., Nomura, W., Miura, T., Igarashi, T., Matsushita, S. and Tamamura, H. A CD4 mimic as an HIV entry inhibitor: Pharmacokinetics. Bioorg. Med. Chem. 21: 7884?7889 , 2013.

2013.07.05  The Mind Exchange Working Group (Antinori A, Arendt G, Grant I, Matsushita S, et al.) Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin Infect Dis. 56(7):1004 -1017, 2013

2013.07.05  Harada S, Yoshimura K, Yamaguchi A, Yusa K, Matsushita S. Impact of antiretroviral pressure on selection of primary HIV-1 envelope sequences in vitro. J. Gen. Virol. 94:933-943, 2013.

2013.07.05  Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov KI, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses. J. Virol. 87:5424-5346, 2013.

2013.07.05  Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H.: CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Bioorganic & Medicinal Chemistry. 21:2518-2526, 2013 .

2013.07.05  Kuwata T, Takaki K, Enomoto I, Kazuhisa Y, and Matsushita S. Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Frontiers in Microbiology/Virology. 4:1-7, 2013.

2013.07.05  Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa, S., Takada, K., Yamamoto, M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S, on behalf of the Epzicom-Truvada study team: Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial. Internal Medicine. 52: 735-744, 2013.

2012年

2012.07.05  Yokoyama M, Naganawa S, Yoshimura K, Matsushita S, Sato H. Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop. PLoS ONE. 7(5): e37530, 2012.

2012.07.05  Ong YT, Kirby KA, Hachiya A, Chiang LA, Marchand B, Yoshimura K, Murakami T, Singh K, Matsushita S, Sarafianos SG. Preparation of biological active single-chain variable antibody fragments that target the HIV-1 gp120 v3 loop. Cellular and Molecular Biology. 58: 71-79, 2012

2011年

2011.07.05  Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S and behalf of Japanese Anti-HIV-1 QD Therapy Study Group. Open-Label Randomized Multicenter Selection Studyof Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine. Internal Medicine. 50: 699-705,2011.

2011.04.24  Narumi, T., Arai, H.,Yoshimura, K.,Harada, S., Nomura, W., Matsushita, S., Tamamura. H. Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem , 19: 6735-6742 ,2011.

2010年

2010.03.14  4. Narumi, T., Ochiai, C., Yoshimura, K., Harada, S., Tanaka,T., Nomura,W., Arai, H., Ozaki, T., Ohashi, N., Matsushita, S., Tamamura, H. :CD4mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorganic & Medicinal Chemistry Letters. 5853- 5858, 2010.

2010.03.14  Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H., Matsushita, S. :Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84:7558-7568, 2010.

2010.03.14  Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J., Matsushita S. HIV-1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91: 1335-1345, 2010. 

2010.03.14  Yamada, Y., Ochiai, C., Yoshimura, K., Tanaka, T., Ohashi, N., Narumi, T., Nomura, W., Harada, S., Matsushita, S., Tamamura, H. CD4 mimics targeting the mechanism of HIV entry. Bioorganic & Medicinal Chemistry Letters 20: 354–358, 2010.

2008年

2008.03.14  Ryo, A., Tsurutani, N., Ohba, K., Kimura, R., Komano, J., Nishi, M., Soeda, H., Hattori,S., , Perrem, K., Yamamoto, M., Chiba, J., Mimaya, J., Yoshimura, K., Matsushita, S., Honda, M., Yoshimura, A., Sawasaki, T., Aoki, I., Morikawa, Y., and Yamamoto, N. SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci U S A. 105:294-299, 2008.

2008.03.14  Ikeda T, Ohsugi T, Kimura T, Matsushita S., Maeda Y, Harada S, Koito A. The anti-retroviral potency of APOBEC1 deaminase from small animal species. Nuleic Acids Research, 36(21): 6859-6871, 2008.

2007年

2007.03.14  Ikeda T, Shibata J, Yoshimura K,Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective HAART.J. Infect. Dis.195:716-725, 2007 .

2007.03.14  Shibata J, Yoshimura K, Honda A.,Koito A, Murakami T. Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. J. Virol. 81:3757-3768,2007

2007.03.14  Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S.: Successful efavirenz dose reduction in HIV-1-infeccted individuals with cytochrome P450 2B6*6 and *26. Clinical Infectious Diseases., 45: 1230-1237, 2007.

2007.03.14  Nakayama E.E., Carpentier W, Costagliola D., Shioda T., Iwamoto A., Debre P, Yoshimura K, Autran B, Matsushita S, Theodorou I. Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 59:511-515, 2007.

2006年

2006.03.14  Eda Y, Takizawa M, Murakami T., Maeda H., Kimachi K., YonemuraH, Koyanagi S, Shiosaki K, Higuchi H, Makizumi K, Nakashima T ,Osatomi K., Tokiyoshi S, Matsushita S, Yamamoto N. Honda M. Sequential immunization with V3 peptides from primary HIV-1 produces cross-neutralizing antibodies against primary isolates with matching narrow neutralization sequence motif.J. Virol. 80:5552-5562,2006.

2006.03.14  Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, Kaizu M, Izumi Y., Yoshino, N., Matsusita, S.,Higuchi, H., Matsui, H., Shinohara, K., Takeuchi, H., Koyanagi, S., Yamamoto, N. and Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affordssterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80:5563-5570, 2006

2006.03.14  Davis DA, Brown CA, Singer KE., Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa, P, Mitsuya H, Yarchoan R Antiviral Res. 72:89-99, 2006

2006.03.14  Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favorable synergism with anti-CCR5 inhibitors. AIDS .20:2065-2073, 2006.

2005年

2005.03.14  Matsushita S., Yoshimura, K., Kimura T., Kamihira, A., Takano, M., Eto, K., Shirasaka, T., Mitsuya, H., Oka, S.: Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term CombivirR containing regimen. J.Clin.Virol. 33:188-193, 2005

2005.03.14  Sakaguchi N, Kimura T., Matsushita S, Fujimura S, Shibata J, Araki M, Sakamoto T, Minoda S, and Kuwahara K.Generation of high-affinity antibody against T cell- dependent antigen in ganp gene- transgenic mouse. J. Immunol. 174:4485-4494,2005.

2005.03.14  Matsushita S, Takahama S., Shibata J., Kimura T., Shiozaki K., Eda Y., Koito A., Murakami T, and Yoshimura K. Ex vivo neutralization of HIV-1 quasispecies by a broadly reactive humanized monoclonal antibody KD247. Human Antibodies. 14:80-88, 2005

2004年

2004.03.14  Tamiya S., Mardy S., Kavlick M.F., Yoshimura K, Mistuya H.  Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 78:12030-12040, 2004.

2003年

2003.03.14  Koito A, Shigekane H, Matsushita S. Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication. Virology, 305:181-191, 2003.

2003.03.14  Koito A,Kameyama Y, Cheng-Mayer C, Matsushita S. Susceptibility of mink (Mustera vision)-derived cells to replication by human immunodeficiency virus type-1. J Virol, 77:5109-511, 2003

2003.03.14  Yoshimura K, Ido E., Akiyama H, Kimura T, Aoki M, Suzuki H., Mitsuya H, Hayami M, Matsushita S. The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV89.6P. J Virol Methods. 112:121-128, 2003.

2002年

2002.03.14  Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M.F., Nagashima, K., Gorelick, R.J., Mardy, S., Tang, C., Summers, M.F., Mitsuya, H.: Amino acid substitutions in gag protein at non-cleavage sited are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961, 2002.

2002.03.14  Matsushita, S. Kimura, T. Advance in treatment strategy and immune reconstruction against HIV-1 infection. Microbiol. Immunol., 46(4):231-239, 2002. [PDF]

2002.03.14  Wang FX, Kimura T, Nishihara K., Yoshimura K.,Koito A, Matsushit S. Emergence of autologous neutralization-resistant variants from pre existing quasispecies during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active anti retroviral therapy (HAART) . J Infect Dis, 185:608-617, 2002.

2002.03.14  Kimura T, Yoshimura K., Nishihara K., Maeda Y, Matsumi S,Koito A, Matsushita S. Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy. J. Infect. Dis., 185:53-60,  2002.

2002.03.14  Yoshimura K, Kato R , Kavlick MF, Nguyen A, Maroun V, Maeda K., Hussain K., Ghosh A., Erickson J, Mitsuya H. A Potent Protease Inhibitor (PI) UIC-94003 Interacting with Main Chains of HIV Protease Active Site Amino Acids and the Development of a Novel Mutation A28S in the Protease of UIC-94003-Resistant HIV. J Virol, 76:1349-1357, 2002.

2001年

2001.03.14  Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., and Mitsuya, H. Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem. 276:35194-35200, 2001.

2001.03.14  Ikegawa M, Matsumoto K, Herrmann S, Iwamoto A, Nakamura T, Matsushita S, Nakamura T, Honjo T, Tashiro K: Elevated plasma SDF-1 protein level in the progression of HIV-1 infection/AIDS. AIDS Res Hum Retrov. 17(7):587-595, 2001

2000年

2000.03.14  Sei, S., Yang, Q. E., O’Neill, D., Yoshimura, K., Nagashima, K., and Mitsuya, H. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J. Virol. 74:4621-33, 2000.

2000.03.14  Falloon, J., Piscitelli, S., Vogel, S., Sadler, B., Mitsuya, H., Kavlick, M. F., Yoshimura, K., Rogers, M., LaFon, S., Manion, D. J., Lane, H. C., and Masur, H. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease- inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-308, 2000.

2000.03.14  Ohrui, H., Kohgo, S., Kitano, K., Sakata, S., Kodama, E., Yoshimura, K., Matsuoka, M., Shigeta, S., and Mitsuya, H. Syntheses of 4′-C-Ethynyl-beta-D-arabino- and 4′-C-Ethynyl-2’deoxy- beta-D-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity. J. Med. Chem. 43:4516-4525, 2000.

2000.03.14  Murakami T, Nakajima N, Nakamura T, Hara A., Uyama E., Mita S, Matsushita S, Uchino M. Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and toxoplasma infection. Internal Medicine 39, 1111-1114, 2000.

2000.03.14  Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J. NMR structure of an anti gp-120 antibody complex with a V3-peptide reveals a surface important for co-receptro binding. Structure 8, 385-395. 2000.

2000.03.14  Matsushita S. Current status and future issues in the treatment of HIV infection. Int. J. Hematol. 72(1):20-27, 2000

2000.03.14  Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both V2 and V3 region of CCR5-tropic human immunodeficiency virus type-1 envelope for reduced sensitivity to macrophage inflammatory protein α J Virol 74(4), 1787-1793, 2000

1999年

1999.03.14  Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci USA. 96:8675-80., 1999.

1999.03.14  Yoshimura K,Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother. 43:2479-83, 1999.

1998年

1998.03.14  Matsumi S, Maeda Y, Kimura T, Matsushita S. Effect of the Th1 and Th2 stimulatory cytokines, IL-12 and IL-4, on HIV-1 specific CTL activity. 12th World AIDS Conference, Appendix 5: 45-50, 1998.

1998.03.14  Wang J, Harada K., Matsushita S, Matsumi S, Zhang Y, Shioda T, Nagai Y, Matsushima K. IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J. Leukocyte Biology., 64:642-649,1998.

1998.03.14  Shoji S, Kazuchika K, Ogata A, Yamataka K., Mukai K., Uda A., Harano S, Matsushita S, Misumi S. An allisteric drug, o’o’-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 tat and NF-ΚB. Biochem. Biophys. Res. Commun., 249, 745-753, 1998.

1998.03.14  Hakata Y, Umemoto T., Matsushita S, Shida H. Involvement of human CRM1 (Exportin 1) in the export and multimerization of the Rex protein of the human T-cell leukemia virus type 1. J. Virol. 72: 6602-6607, 1998.

タイトルとURLをコピーしました